Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy

Gene Therapy

Volumn 9, Issue 18, 2002, Pages 1214-1220

  Oshima, Y ^a   Sakamoto, T ^a   Hisatomi, T ^a   Tsutsumi, C ^a   Ueno, H ^a   Ishibashi, T ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Gene therapy; Retinal detachment; TGF ; Type II TGF receptor; Vitreoretinopathy

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONJUNCTIVA; CONTROLLED STUDY; DISEASE COURSE; DRUG TISSUE LEVEL; FIBROBLAST; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; HISTOPATHOLOGY; MEMBRANE FORMATION; NONHUMAN; OPHTHALMOSCOPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RATING SCALE; RETINA DETACHMENT; SIGNAL TRANSDUCTION; SOLUBILITY; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM; VITRECTOMY; VITREORETINOPATHY;

ADENOVIRIDAE; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUNDUS OCULI; GENE THERAPY; GENETIC VECTORS; RABBITS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

ADENOVIRIDAE; ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0036740438     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301789     Document Type: Article

References (25)

1. Retina Society Terminology Committee The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121-125.
2. Glaser BM, Lemor M. Pathology of proliferative vitreoretinopathy. In: Ryan SJ (ed.). Retina. CV Mosby: St Louis, 1994, pp 2249-2263.
3. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 1992; 36: 373-384.
4. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999; 40: 705-712.
5. Esser P et al. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis. Exp Eye Res 1997; 65: 365-378.
6. Gonzalez-Avila G et al. Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy. Ophthalmology 1995; 102: 1400-1405.
7. Hardwick C et al. Pathologic human vitreous promotes contraction by fibroblasts. Implications for proliferative vitreoretinopathy. Arch Ophthalmol 1995; 113: 1545-1553.
8. Connor Jr. TB et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989; 83: 1661-1666.
9. Shull MM et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
10. Kulkarni AB et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774.
11. Sanford LP et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997; 124: 2659-2670.
12. Ueno H et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 2000; 11: 33-42.
13. Sakamoto T et al. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis. Gene Therapy 2000; 7: 1915-1924.
14. Honda M et al. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Therapy 2000; 7: 978-985.
15. Shiose S et al. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci 2000; 41: 2395-2403.
16. Sakamoto T et al. Retinal functional change caused by adenoviral vector-mediated transfection of LacZ gene. Hum Gene Ther 1998; 9: 789-799.
17. Sakamoto T et al. A vitrectomy improves the transfection efficiency of adenoviral vector-mediated gene transfer to Muller cells. Gene Therapy 1998; 5: 1088-1097.
18. Yamamoto H et al. Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture. J Biol Chem 1996; 271: 16253-16259.
19. Glorioso JC, Naldini L, Kay MA. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
20. Liu YC, Kawagishi M, Kameda R, Ohashi H. Characterization of a fusion protein composed of the extracellular domain of c-kit and the Fc region of human IgG expressed in a baculovirus system. Biochem Biophys Res Commun 1993; 197: 1094-1102.
21. Liu YC et al. Processing of a fusion protein by endoprotease in COS-1 cells for secretion of mature peptide by using a chimeric expression vector. Proc Natl Acad Sci USA 1993; 90: 8957-8961.
22. Ueno H et al. Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vase Biol 1995; 15: 2246-2253.
23. Tahara Y et al. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy. Curr Eye Res 1999; 19: 323-329.
24. Ito S et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1999; 237: 691-696.
25. Fastenberg DM, Diddie KR, Dorey K, Ryan SJ. The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol 1982; 93: 565-572.